Skip to main content
Have a personal or library account? Click to login
[F-18] FDG-PET/CT parameters as predictors of outcome in inoperable NSCLC patients Cover

[F-18] FDG-PET/CT parameters as predictors of outcome in inoperable NSCLC patients

Radiology and Oncology
Volume 49 (2015): Issue 4 (December 2015)
By: ,  ,  ,  ,  ,  ,  ,  ,  ,   and    
Open Access
|Nov 2015
References

References

  1. 17th edition. Edge S, Byrd DR, Compton CC, FritzGreene FL, Trottieditors. New York: Springer Verlag; 2010.
    Search in Google Scholar
  2. 2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010.2010;277-300.
    Open DOISearch in Google Scholar
  3. 3. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.2013;1374-403.
    Open DOISearch in Google Scholar
  4. 4. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0,No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available at:.
    Search in Google Scholar
  5. 5. Schild SE, Tan AD, Wampfler JA, Ross HJ, Yang P, Sloan JA. A new scoring system for predicting survival in patients with non-small cell lung cancer.2015;1334-43.
    Open DOISearch in Google Scholar
  6. 6. McCoach CE, Kelly K. Treatment paradigms in advanced non-small-cell lung cancer.2013;629-39.
    Search in Google Scholar
  7. 7. Van Rens MT, de la Riviere AB, Elbers HR, van Den Bosch JM. Prognostic assessment of 2361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II and IIIa.2000;374-79.
    Open DOISearch in Google Scholar
  8. 8. Socinski MA, Morris DE, Masters GA, Lilenbaum R; American College of Chest Physicians. Chemotherapeutic management of stage IV non-small cell lung cancer.2003;226S-43S.
    Open DOISearch in Google Scholar
  9. 9. Aydiner A, Sen F, Saglam EK, Oral EN, Eralp Y, Tas F, et al. Induction chemo-therapy with triweekly docetaxel and cisplatin followed by concomitant chemoradiotherapy with or without surgery in stage III non-small-cell lung cancer: a phase II study.2011;286-92.
    Open DOISearch in Google Scholar
  10. 10. Masters GA, Temin S, Azzoli CG, Giaccone G, Baker S Jr, Brahmer JR, et al. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.2015;3488-515.
    Open DOISearch in Google Scholar
  11. 11. Zwitter M, Kovac V, Smrdel U, Vrankar M, Zadnik V. Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: a randomized phase II clinical trial.2009;1148-55.
    Open DOISearch in Google Scholar
  12. 12. Noonan K, Tong KM, Laskin J, Zheng YY, Melosky B, Sun S, et al. Evaluation of a ‘Watch and Wait’ Approach for Chemotherapy in Patients with Newly Diagnosed Advanced Non-small Cell Lung Cancer from a Diverse Community Population.2015;505-13.
    Open DOISearch in Google Scholar
  13. 13. Mac Manus MP, Hicks RJ, Matthews JP, McKenzie A, Rischin D, Salminen EK, et al. Positron emission tomography is superior to computed tomography scanning for response- assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer.2003;1285-92.
    Open DOISearch in Google Scholar
  14. 14. Ryu JS, Choi NC, Fischman AJ, Lynch TJ, Mathisen DJ. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology.2002;179-87.
    Open DOISearch in Google Scholar
  15. 15. Grgic A, Yüksel Y, Gröschel A, Schäfers HJ, Sybrecht GW, Kirsch CM, et al. Risk stratification of solitary pulmonary nodules by means of PET using (18) F-fluorodeoxyglucose and SUV quantification.2010;1087-94.
    Open DOISearch in Google Scholar
  16. 16. Zwitter M, Stanic K, Rajer M, Kern I, Vrankar M, Edelbaher N, et al. Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations.2014;361-8.
    Open DOISearch in Google Scholar
  17. 17. Olivier A, Petyt G, Cortot A, Scherpereel A, Hossein-Foucher C. Higher predictive value of tumour and node [18F]-FDG PET metabolic volume and TLG in advanced lung cancer under chemotherapy.2014;908-15.
    Open DOISearch in Google Scholar
  18. 18. Hoang JK, Hoagland LF, Coleman RE, Coan AD, Herndon JE 2nd, Patz EF Jr. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma.2008 20;1459-64.
    Open DOISearch in Google Scholar
  19. 19. Hashimoto Y, Tsujikawa T, Kondo C, Maki M, Momose M, Nagai A, et al. Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5.2006;426-31.
    Search in Google Scholar
  20. 20. Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, et al. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.2012;27-38.
    Open DOISearch in Google Scholar
  21. 21. Lee P, Bazan JG, Lavori PW, Weerasuriya DK, Quon A, Le QT, et al. Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non–small-cell lung cancer.2012;52-8.
    Open DOISearch in Google Scholar
  22. 22. Xie P, Yue JB, Zhao HX, Sun XD, Kong L, Fu Z, et al. Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma.2010;883-9.
    Open DOISearch in Google Scholar
  23. 23. Giorgetti A, Sorace O, Pisani P, Salvadori PA, Mariani G. Accuracy of Qualitative and Semiquantitative Analysis of 18FDG Positron Emission Tomography Scans in the Evaluation of Primary and Metastatic Lesions.2000;182
    Open DOISearch in Google Scholar
  24. 24. Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, et al. “ErbB receptors: from oncogenes to targeted cancer therapies”.2007;2051-8.
    Open DOISearch in Google Scholar
  25. 25. Ma BB, Hui EP, Mok TS. Population-based differences in treatment outcome following anticancer drug therapies.2010;75-84.
    Open DOISearch in Google Scholar
  26. 26. Storto G, Nicolai E, Salvatore M. [18F]FDG-PET-CT for early monitoring of tumor response: when and why.2009;167-80.
    Search in Google Scholar
  27. 27. Berghmans T, Dusart M, Paesmans M, Hossein-Foucher C, Buvat I, Castaigne C, et al. European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project.2008;6-12.
    Open DOISearch in Google Scholar
  28. 28. Tong AN, Han SR, Yan P, Gong H, Zhao H, Yao H, et al. Prognostic value of FDG uptake in primary inoperable non-small cell lung cancer.2014;780
    Open DOISearch in Google Scholar
  29. 29. Lebioda A, Makarewicz R, Małkowski B, Dancewicz M, Kowalewski J, Windorbska W. Measurement of primary tumor volume by PET-CT to evaluate risk of mediastinal nodal involvement in NSCLC patients with clinically negative N2 lymph nodes.2013;76-81.
    Open DOISearch in Google Scholar
  30. 30. Casali C, Cucca M, Rossi G, Barbieri F, Iacuzio L, Bagni B, et al. The variation of prognostic significance of Maximum Standardized Uptake Value of [18F]-fluoro-2-deoxy-glucose positron emission tomography in different histological subtypes and pathological stages of surgically resected Non-Small Cell Lung Carcinoma.2010;187-93.
    Open DOISearch in Google Scholar
DOI: https://doi.org/10.1515/raon-2015-0043 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 320 - 326
Submitted on: May 19, 2015
Accepted on: Sep 11, 2015
Published on: Nov 27, 2015
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Non-small-cell lung cancer,
[F-18] FDG PET/CT,
quantitative assessment,
glycolytic activity,
survival
Related subjects:
Medicine,
Clinical medicine,
Radiology

© 2015 Antonio Nappi, Rosj Gallicchio, Vittorio Simeon, Anna Nardelli, Alessandra Pelagalli, Angela Zupa, Giulia Vita, Angela Venetucci, Michele Di Cosola, Francesco Barbato, Giovanni Storto, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 49 (2015): Issue 4 (December 2015)
Previous article
Next article